Vaxcyte (PCVX) Operating Leases (2021 - 2026)

Vaxcyte (PCVX) has reported Operating Leases for 6 consecutive years, with $116.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Leases rose 43.43% year-over-year to $116.3 million; the TTM figure through Mar 2026 stood at $116.3 million (up 43.43% YoY), while the FY2025 annual figure was $111.5 million, up 70.9% from the prior year.
• Operating Leases rose to $116.3 million in Q1 2026 per PCVX's latest filing, from $111.5 million in the prior quarter.
• Across five years, Operating Leases topped out at $116.3 million in Q1 2026 and bottomed at $7.8 million in Q3 2023.
• Historically, Operating Leases has averaged $41.3 million across 5 years, with a median of $18.3 million in 2024.
• Annual changes were most pronounced in 2022 — Operating Leases jumped 6371.11% — and 2023, when it plunged 41.74%.
• Vaxcyte's Operating Leases stood at $12.9 million in 2022, then soared by 71.4% to $22.1 million in 2023, then jumped by 194.96% to $65.2 million in 2024, then jumped by 70.9% to $111.5 million in 2025, then increased by 4.34% to $116.3 million in 2026.
• Business Quant data shows PCVX's Operating Leases at $116.3 million in Q1 2026, $111.5 million in Q4 2025, and $78.7 million in Q3 2025.